We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Serum Biomarker Determined for Colorectal Cancer

By LabMedica International staff writers
Posted on 02 Jul 2013
A highly sensitive blood test can detect cancer related micro-ribonucleic acid (miRNA) before any signs of the disease manifests. More...


Increased expression of circulating miRNAs could be indicative of miRNAs secreted from a tumor, raising the overall diagnostic specificity of biomarkers, especially if they can be measured in blood or serum samples.

Scientists at the Baylor Research Institute (Dallas, TX, USA) analyzed 568 serum and tissue specimens that were obtained from healthy volunteers and consecutively enrolled patients with colorectal adenomas and cancers at the Mie University Medical Hospital (Tsu, Japan), between January 1, 2005 and December 31, 2010.

MiRNA extraction from serum and culture media samples was performed with miRNeasy RNA isolation Kits (Qiagen; Valencia, CA, USA), whereas miRNA extraction from formalin-fixed and paraffin-embedded (FFPE) samples was performed using RecoverAll Total Nucleic Acid Isolation Kits (Ambion Inc.; Austin, TX, USA). The TaqMan miRNA quantitative reverse-transcription polymerase chain reaction (qRT-PCR; Applied Biosystems; Foster City, CA, USA) were used to detect and quantify miRNA expression.

By measuring levels of miR-21 in the blood, the scientists could accurately identify up to 92% of patients with colorectal cancer. Even more importantly, not only is this test good for noninvasively identifying patients who already have colorectal cancer, but it can accurately identify up to 82% of patients with advanced colonic polyps, which present the highest risk for developing into colorectal cancers several years later in life.

Ajay Goel, PhD, the lead investigator said, “The development of this biomarker is highly encouraging because high mortality rates associated with colorectal cancer is a consequence of late detection of this disease, underscoring the need for improved early detection, prevention, risk assessment, and intervention. Michael Ramsay, MD, the president of Baylor Research Institute, added, “This blood-based test could be transformative in how we screen patients for colorectal cancer; it would save lives and could result in major savings of health care dollars.” The study was published on May 23, 2013, in the Journal of the National Cancer Institute.

Related Links:

Baylor Research Institute
Mie University Medical Hospital
Qiagen



New
Gold Member
Automatic CLIA Analyzer
Shine i9000
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Collection and Transport System
PurSafe Plus®
Gram-Negative Blood Culture Assay
LIAISON PLEX Gram-Negative Blood Culture Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: A blood biomarker test offers a clearer prognosis after cardiac arrest (Photo courtesy of Adobe Stock)

Blood Biomarker Improves Early Brain Injury Prognosis After Cardiac Arrest

After a cardiac arrest, many patients remain unconscious for days, leaving doctors and families facing uncertainty about whether meaningful recovery is possible. Current tools to assess brain damage, including... Read more

Hematology

view channel
Image: Residual leukemia cells may predict long-term survival in acute myeloid leukemia (Photo courtesy of Shutterstock)

MRD Tests Could Predict Survival in Leukemia Patients

Acute myeloid leukemia is an aggressive blood cancer that disrupts normal blood cell production and often relapses even after intensive treatment. Clinicians currently lack early, reliable markers to predict... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.